BioCentury
ARTICLE | Clinical News

Adaptimmune’s T cell therapy against MAGEA4 enters Phase I in solid tumors

May 18, 2017 6:39 PM UTC

Adaptimmune Therapeutics plc (NASDAQ:ADAP) began a Phase I trial to evaluate escalating doses of MAGE A4 TCR (MAGE-A4 SPEAR T-cell therapy, MAGEA4 TCR) in about 32 patients who are HLA-A*02-positive with locally advanced, inoperable or metastatic solid tumors expressing melanoma-associated antigen A4 (MAGEA4).

The open-label, U.S. trial’s co-primary endpoints are safety, dose-limiting toxicities (DLTs), persistence of genetically modified T cells and replication-competent lentivirus (RCL) in genetically modified T cells. Secondary endpoints include overall response rate (ORR), time to first response, duration of response, duration of stable disease, progression-free survival (PFS) and overall survival (OS)...